Category

Daily Briefs

Daily Brief Event-Driven: Significant Developments Emerged Today for Korea’s Value-Up and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Significant Developments Emerged Today for Korea’s Value-Up
  • Merger Arb Mondays (22 Apr) – Shinko, Inageya, C&F Logistics, Hollysys, Azure, Qantm IP, Tietto
  • EQD / NSE Volatility Update / 15-Apr-24 to 19-Apr-24
  • Nippon Steel/United States Steel Corp


Significant Developments Emerged Today for Korea’s Value-Up

By Sanghyun Park

  • Deputy PM Choi Sang-mok commits to aggressively pursue separate taxation of dividend income, marking a shift towards concrete action for value-up policies.
  • Ever since the introduction of the Value-up policy earlier this year, the primary incentive championed by the local capital market has been the separate taxation of dividend income.
  • Hence, the government’s official commitment to this marks a crucial step in reshaping the Value-up momentum.

Merger Arb Mondays (22 Apr) – Shinko, Inageya, C&F Logistics, Hollysys, Azure, Qantm IP, Tietto

By Arun George


EQD / NSE Volatility Update / 15-Apr-24 to 19-Apr-24

By Sankalp Singh

  • Unprecedented levels of FII option-buying & increasing geo-political risk causing IVs to re-price higher.
  • Skew/ Smile characteristics of the Vol Surface reflect increased risk aversion but not it panic mode – yet.
  • BankNifty IVs exhibiting unusual “kink-in-the-curve”. Enter barbell structures to position for reversion in curve shape.

Nippon Steel/United States Steel Corp

By Jesus Rodriguez Aguilar

  • On 18 April, a White House official said that any review of the deal between Nippon Steel Corporation (5401 JP) and United States Steel (X US) by CFIUS will continue as scheduled.
  • X shares trade at ~5.2x on NTM IBES-consensus EBITDA given priced-in deal risk vs. implied 7x at the time of the winning NSC’s bid, and look attractive relative to comparables.
  • There remains a possibility that Nippon could finalize the takeover after the U.S. presidential election, presenting potential upside.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: TSMC Just Provided Substantial Visibility into Their Long-Term Growth Estimate; ASML Adds Color and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • TSMC Just Provided Substantial Visibility into Their Long-Term Growth Estimate; ASML Adds Color
  • JD.com (JD US / 9618 HK):  Announced 2.8% Share Buyback In 1Q24 + My 1Q24 Preview
  • Taiwan Dual-Listings Monitor: TSMC Breaks Down From Extreme, UMC Discount Near Historical Low
  • Innovent Biologics(1801 HK)– More than Just a GLP-1 Play
  • China Healthcare Weekly (Apr.21) – M&As in Biotech, Capital Is Bullish on Non-Tumor Sectors, Tofflon
  • Monthly Chinese Express Tracker | March ASPs Fell, Again | Volumes Moderated, Including X-Border
  • Shift: On a Road to Recovery
  • TSMC, ASML, VAT Group, and Alphawave Earnings
  • CanSino Biologics (6185.HK/688185.CH) – 2024 Is the Best Time to Bottom-Fish This Stock
  • Bell Financial Group Ltd – Strong start to FY24 with Q1 PBT +60%


TSMC Just Provided Substantial Visibility into Their Long-Term Growth Estimate; ASML Adds Color

By Vincent Fernando, CFA

  • TSMC and ASML reported 1Q24 results last week; both stocks have fallen post results, impacted by global concerns despite a strong outlook for these two leaders into 2025E.
  • TSMC guided for strong growth not just in 2024E, but if one digs into management’s comments, they actually provided strong visibility into their 2028E internal revenue expectations.
  • For ASML, its EUV product business is the key indicator to watch. We believe TSMC shares will continue to re-rate even through a period of global economic softness.

JD.com (JD US / 9618 HK):  Announced 2.8% Share Buyback In 1Q24 + My 1Q24 Preview

By Steve Zhou, CFA

  • JD.com (9618 HK) announced this week that it has repurchased 2.8% of the outstanding shares of the company in the first quarter of 2024. 
  • Improved shareholder returns is a key thesis for the stock, given that there is little market expectation on such given limited track record.
  • A positive catalyst on full year performance could be the government’s announced stimulus policy for home appliance in April this year (trading old for new).

Taiwan Dual-Listings Monitor: TSMC Breaks Down From Extreme, UMC Discount Near Historical Low

By Vincent Fernando, CFA

  • TSMC: +9.2% Premium, Major Breakdown From Previous Historically Extreme High
  • UMC: -1.9% Discount, Is Near Low End of Historical Range
  • ASE: +10.4%; ADR Short Interest Jumps to Very High Level vs. History

Innovent Biologics(1801 HK)– More than Just a GLP-1 Play

By Avien Pillay

  • Innovent is most well-known as the developer of mazdutide in China, however this is overshadowing a strong portfolio of oncology drugs in a very high growth market.
  • China’s approach to healthcare is being defined by having the biggest diabetic population, over 4 million new cancer cases per year, and over 100 million living with obesity.
  • We expect the valuation gap between the two first-to-market GLP-1 drugs, and competition to close. Oncology drug sales and valuations will continue its growth trajectory.

China Healthcare Weekly (Apr.21) – M&As in Biotech, Capital Is Bullish on Non-Tumor Sectors, Tofflon

By Xinyao (Criss) Wang

  • We have seen four transactions of MNC acquiring Chinese Biotech companies. However, this does not mean that domestic big pharmaceutical companies will also participate in the acquisition of small Biotech.
  • The underlying investment logic of innovative drug is undergoing changes. Non-oncology fields, such as autoimmunity, CNS, endocrine metabolism, and ophthalmology will be the main hot directions of investment and R&D.
  • Shanghai Tofflon Science A (300171 CH) is still in downward trend. We’re not optimistic about its 2023 results. We don’t recommend bottom-fish this stock unless there is a major catalyst.

Monthly Chinese Express Tracker | March ASPs Fell, Again | Volumes Moderated, Including X-Border

By Daniel Hellberg

  • ASPs remain under pressure as STO, J&T gain volume share in ground segment
  • March showed a surprising slowdown in pace of international volume growth
  • We believe Q423 and Q124 company-level profitability will mostly disappoint

Shift: On a Road to Recovery

By Shifara Samsudeen, ACMA, CGMA

  • Shift Inc (3697 JP) ’s share price has been down more than 50% YTD with the release of 1QFY08/2024 results in January 2024 which saw a drop in margins.
  • The company’s aggressive investment in HR and system reinforcement led to a decline in margins, however, margins saw a QoQ improvement in 2QFY08/2024.
  • Despite there being an improvement in 2Q and the company expecting the margins to bounce back in 4Q, Shift’s share price has continued to fall.

TSMC, ASML, VAT Group, and Alphawave Earnings

By Douglas O’Laughlin

  • It’s time for the main event: earnings are upon us. As is customary, let’s start with TSMC, move to ASML and Alphawave, and then discuss VAT Group.
  • TSM revenue is above guidance, gross margins are a bit ahead of the midpoint, and operating margins are at the high end of guidance.
  • First, while this is a good result, semiconductors are due for a correction. I wrote about this in March, and SOXX has quietly crept downwards since then.

CanSino Biologics (6185.HK/688185.CH) – 2024 Is the Best Time to Bottom-Fish This Stock

By Xinyao (Criss) Wang

  • We would see CanSino’s performance pick up obviously in 2024 – Revenue of meningococcal vaccines would up about 50% YoY. Both R&D and SG&A expenses would show a declining trend.
  • Starting from 2025, CanSino’s product matrix will become more diverse.Its financial performance will enter a virtuous cycle. Revenue in 2025 may exceed expectations, depending on the approval time of PCV13i.
  • CanSino is one of the few domestic vaccine companies that has ability to explore the international market. Mispricing/expectation differences in the market will give investors the opportunity for excess returns.

Bell Financial Group Ltd – Strong start to FY24 with Q1 PBT +60%

By Research as a Service (RaaS)

  • Bell Financial Group Ltd (ASX:BFG) is a diversified provider of financial products and software solutions within, and increasingly outside, its traditional full-service stockbroking business.
  • A Q1 FY24 trading update provided at the group’s AGM on 19 April points to revenue growth of 17% and PBT growth of 60% to $9.3m, with all divisions said to be profitable.
  • This compares to a RaaS H1 FY24 PBT growth estimate of 69%, placing the group on track to achieve our H1 estimates.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: Are We In For A 1970s Style Inflation Revival? and more

By | Daily Briefs, Macro

In today’s briefing:

  • Are We In For A 1970s Style Inflation Revival?
  • What’s Bothering the U.S. Stock Market?
  • Steno Signals #96 – A major devaluation of the CNY could be imminent
  • Shipping Watch: No news is bad news (for inflation)
  • US Rates: Tax Season, Debt Ceiling, and Reserves
  • Portfolio Watch: Sitting on our hands
  • Tracking & Nowcasting G3 GDP


Are We In For A 1970s Style Inflation Revival?

By Cam Hui

  • Fears of a repeat of the 1970s inflation cycle are overblown. Inflationary expectations are well anchored and the pace of wage increases are decelerating.
  • However, the IMF has warned of the risks of the deteriorating U.S. fiscal picture and investors have to acknowledge that we are in an age of fiscal dominance.
  • For investors, the evolution of risk appetite will depend on changes in inflationary expectations and term premium.

What’s Bothering the U.S. Stock Market?

By Cam Hui

  • Stock prices have had to contend with a trifecta of woes: Fear of a hawkish pivot by the Fed; Strong USD; and Geopolitical risk and rising oil prices.
  • The stock market is very oversold and ripe for a relief rally. The key question is: does the bounce represent a durable bottom or is there more downside ahead?
  • As investors and traders wait for the inevitable bounce, here are what we are watching.

Steno Signals #96 – A major devaluation of the CNY could be imminent

By Andreas Steno

  • China is preparing something BIG. That seems more and more obvious to me by the week now. The question is what that BIG thing is.
  • China reported a strong 5.2% YoY Q1 despite troubles on the ground, local financial institutions are hoarding bonds because of a weak credit demand growth picture and the Chinese authorities seem to be stockpiling like crazy.
  • We have seen plenty of tin-foil theories speculating in the reasons behind those Chinese actions, but maybe China is just preparing a major one-off devaluation of the CNY?

Shipping Watch: No news is bad news (for inflation)

By Andreas Steno

  • Headlines in the beginning of 2024 were dominated by shipping and logistic troubles but over the last months that has almost died completely down.
  • With “no news” we continue to see spill-overs to goods inflation in coming months.
  • In general freight rates have been falling since Jan high but still remain some 50% above 2023 levels

US Rates: Tax Season, Debt Ceiling, and Reserves

By At Any Rate

  • Tax receipts post-tax day are tracking about 15% above last year’s pace, below 2022 levels.
  • Increase in electronic filings leads to quicker processing of tax receipts.
  • TGA balances have increased by $250 billion to $930 billion, in line with 2022 trends.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Portfolio Watch: Sitting on our hands

By Andreas Steno

  • Welcome to our weekly Portfolio Watch.
  • We have returned -0,87% in our Macro Alpha Portfolio this week as of the time of writing, which is a decent return profile given the drawdowns seen across the asset universe.
  • We have been sitting on our hands due to the trickiness of timing the missiles flying back and forth in the Middle East and due to our lack of conviction that the timing is right to re-enter riskier bets.

Tracking & Nowcasting G3 GDP

By Thomas Lam

  • I harness my hybrid nowcasting framework to track the growth prospects of the G3 (US, Euro Area and Japan) economies
  • Overall, G3 real GDP growth seems to be tracking potentially slower, though uneven across the individual economies, in 1Q 2024
  • My nowcasts imply that the G3 economies are unlikely to wiggle uniformly in the first-half of 2024 on balance

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Lynas Corp Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • (Mostly) Asia-Pac M&A: Lynas, Tietto Minerals, JSR, Shinko Electric, TDCX


(Mostly) Asia-Pac M&A: Lynas, Tietto Minerals, JSR, Shinko Electric, TDCX

By David Blennerhassett


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Hollysys Automation Technologies, Intuitive Surgical and more

By | Daily Briefs, United States

In today’s briefing:

  • Weekly Deals Digest (21 Apr) – Hollysys, Shinko, Inageya, Hang Lung, Kokusai, HD Hyundai Marine
  • Intuitive Surgical (ISRG US): Beat-And-Raise 1Q24; Rising Demand for Robotic Surgery Propels Growth


Weekly Deals Digest (21 Apr) – Hollysys, Shinko, Inageya, Hang Lung, Kokusai, HD Hyundai Marine

By Arun George


Intuitive Surgical (ISRG US): Beat-And-Raise 1Q24; Rising Demand for Robotic Surgery Propels Growth

By Tina Banerjee

  • In 1Q24, Intuitive Surgical (ISRG US) reported 11% YoY revenue growth to $1.89B, driven by growth in da Vinci procedure volume and an increase in the installed base of systems.
  • Worldwide da Vinci procedures grew 16%, matching the higher end of prior guidance range. The company placed 313 da Vinci surgical systems, including eight newly approved da Vinci 5.
  • Even after considering blip in bariatric surgery, delayed tender in China, and no benefit of patient backlog, the company has raised 2024 worldwide da Vinci procedure growth guidance to 14–17%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Indonesia: Medikaloka Hermina and more

By | Daily Briefs, Indonesia

In today’s briefing:

  • Medikaloka Hermina (HEAL IJ) – Increasing Patient Velocity and Occupancy


Medikaloka Hermina (HEAL IJ) – Increasing Patient Velocity and Occupancy

By Angus Mackintosh

  • Medikaloka Hermina (HEAL IJ) booked a strong recovery in revenues and profits in FY2023 driven by rapidly rising inpatient and outpatient volume growth with JKN patient share rising. 
  • The company also saw significant improvements in working capital in 2023 and will step up its capex and hospital expansion in FY2024E helping to drive growth. 
  • Medikaloka Hermina is differentiated by its women & children specialisation, higher JKN exposure, and its doctor partnership model. It trades at a discount to peers with higher growth expectations. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: Marksans Pharma and more

By | Daily Briefs, India

In today’s briefing:

  • Marksans Pharma- Forensic Analysis


Marksans Pharma- Forensic Analysis

By Nitin Mangal

  • Marksans Pharma (MRKS IN) has done well in recent years, growing at 15.2% on a 5Y CAGR.  
  • The company has a good balance sheet, strong cash generation and also witnessed a recent uptick on the margins side. UK business especially has been the cash cow.
  • However, there are few impairment indicators; few subsidiaries are not audited while bad debts have appeared in the books lately. Company also has few disclosure issues.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: Pasona Group, Japan Hotel Reit Investment and more

By | Daily Briefs, Japan

In today’s briefing:

  • Last Week in Event SPACE: Pasona/Benefit One, Hang Lung Properties, Hollysys, Azure Minerals
  • Short Note: USDJPY Breaking 154: Positive for RE, Buy Japan Hotel REIT, Buy Japan RE


Last Week in Event SPACE: Pasona/Benefit One, Hang Lung Properties, Hollysys, Azure Minerals

By David Blennerhassett


Short Note: USDJPY Breaking 154: Positive for RE, Buy Japan Hotel REIT, Buy Japan RE

By Jacob Cheng

  • USDJPY is breaking 154, almost 20-year high.  In general, weaker Yen is positive for investment in real estate as properties look cheaper from a foreign investor perspective
  • Yen weakness is also positive to tourism in Japan, as weak currency will drive tourist arrival and boost tourism
  • We like Japan Hotel REIT on the back of attractive valuation and weaker Yen.  We also like other Japan RE names like 8801 and 8802

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Industrials: Pasona Group, Evergreen Marine Corp and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Last Week in Event SPACE: Pasona/Benefit One, Hang Lung Properties, Hollysys, Azure Minerals
  • Monthly Container Shipping Tracker | March Volumes Strong | Q1 Margins Likely Up Y/Y (April 2024)


Last Week in Event SPACE: Pasona/Benefit One, Hang Lung Properties, Hollysys, Azure Minerals

By David Blennerhassett


Monthly Container Shipping Tracker | March Volumes Strong | Q1 Margins Likely Up Y/Y (April 2024)

By Daniel Hellberg

  • Our analysis suggests container rate momentum remained +ive in March
  • Despite higher fuel expense, core container margins likely rose Y/Y in Q124
  • Our L/S pair trade? It’s worked, a little, but Evergreen shares have stayed firm

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Taiwan Semiconductor (TSMC), Hollysys Automation Technologies and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • TSMC. How To Turn Chicken Salad Into Chicken Sh*t
  • Weekly Deals Digest (21 Apr) – Hollysys, Shinko, Inageya, Hang Lung, Kokusai, HD Hyundai Marine


TSMC. How To Turn Chicken Salad Into Chicken Sh*t

By William Keating

  • Q124 revenues of $18.87 billion, marginally above the high end of the guided range, up 12.9% YoY and down 3.8% QoQ. Guided Q224 +6% QoQ.  Maintained full year 2024 outlook
  • Unnecessary, minor downward revisions for semi & foundry growth, combined with confusion about the reason triggered an allergic reaction on the markets. TSMC down ~8% since.
  • SMCI plunged 23% by Friday close, ARM down 16.9%, NVIDIA down 10%, AMD & Micron down ~5% etc. Nice one, TSMC!

Weekly Deals Digest (21 Apr) – Hollysys, Shinko, Inageya, Hang Lung, Kokusai, HD Hyundai Marine

By Arun George


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars